Status:
COMPLETED
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Lead Sponsor:
Pfizer
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Second...
Eligibility Criteria
Inclusion
- Histologically and/or cytologically confirmed to have advanced renal cell carcinoma (RCC)
- Majority component of conventional clear-cell type is mandatory
- At least 1 measurable lesion (per RECIST)
Exclusion
- Prior systemic treatment for RCC
- Evidence of current or prior central nervous system (CNS) metastases
- Cardiovascular disease
- Pregnant or nursing women
- Additional criteria applies
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2015
Estimated Enrollment :
791 Patients enrolled
Trial Details
Trial ID
NCT00631371
Start Date
April 1 2008
End Date
April 1 2015
Last Update
April 27 2016
Active Locations (172)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology Oncology Services of Arkansas
Little Rock, Arkansas, United States, 72205
2
South County Hematology/Oncology
Chula Vista, California, United States, 91911
3
Cancer Center Oncology Medical Group
La Mesa, California, United States, 91942
4
UCLA Medical Center
Los Angeles, California, United States, 90095-1694